Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep Completes Recruitment for Part A of TACTI-002 trial (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is...read more

Immutep receives A$1,437,826 R&D Tax Incentive (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,437,826 cash rebate from the Australian Federal Gover...read more

Immutep announces improving data from TACTI-002 ph II trial (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. This data relates to the cut-off date of 4 May 2020 and shows improving efficacy result...read more

Immutep Reports First Results from INSIGHT-004 Study (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report first interim data from its ongoing INSIGHT-004 Phase I clinical trial. The study is a phase I trial evaluating the combination of Immut...read more

Immutep Receives A$3.6 Million R&D Tax Incentive from French Government (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“or “the Company”), a biotechnology company developing novel immunotherapy treatments forcancer and autoimmune diseases, is p...read more

Immutep granted Japanese patent for eftilagimod alpha (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is ...read more

Ingenia security purchase plan (ASX:INA)

Ingenia Communities Group (ASX:INA) announces that further to its ASX Announcement on 30 April 2020, the Security Purchase Plan (SPP) is now open for Eligible Ingenia Security Holders to apply for u...read more

Immutep, Cleansing Notice (ASX:IMM)

Immutep Limited (ASX Code: IMM) – Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) This notice is given by Immutep Limited ACN 009 237 889 (Company) under section 708A(5)(...read more

Imugene HER-Vaxx Phase 2 Clinical Update (ASX:IMM)

Highlights: Independent Data Monitoring Committee confirms HER-Vaxx safety and recommends study continuation without modification Patients receiving HER-Vaxx cancer immunotherapy responding posi...read more

Ingenia successfully completes institutional placement (ASX:INA)

Highlights Strong investor demand from existing and new domestic and offshore investors Capital raised to provide funding flexibility to grow the Group’s asset base as opportunities emerge ...read more

Ingenia Communities Group, Equity Raise Presentation (ASX:INA)

Ingenia Communities Group (INA) provides its Equity Raising Presentation which is authorised for release by the Ingenia Communities Group Board. For further information, please download the...read more

Ingenia equity raise to deliver growth and sector leadership (ASX:INA)

Ingenia Communities Group (ASX:INA) (Ingenia or the Group) today announced an institutional placement (the Placement) to raise $150.0 million and a Security Purchase Plan (the SPP) to raise up to a ...read more

Ingenia Communities Group, Trading Halt (ASX:INA)

Ingenia Communities Group (the “Group”) (ASX: INA), requests a trading halt to be applied with effect from the commencement of trading on Thursday 30 April 2020, pursuant to ASX Listing ...read more

Immutep, INSIGHT-004 and TACTI-002 data to be presented at ASCO (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data are scheduled to be presented in two poster presentations during the Amer...read more